Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06714084 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CNCMT：a Multi-center, Prospective, Single-arm Study

Study acronym: CNCMT
StatusEnrolling by Invitation
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Dec 31, 2025 → Dec 31, 2026
See other at-risk trials from Hubei Cancer Hospital

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Dec 31, 2025 to Dec 31, 2026
    • Eligibility criteria revised
    • Study description expanded, about 29 words
    • Collaborators: details revised at 1 of 2 entries
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To evaluate the safety and efficacy of Cadonilimab in neoadjuvant chemotherapy and maintenance therapy for high-risk advanced cervical cancer receiving concurrent chemoradiotherapy
Trial Details
NCT Number NCT06714084
Lead Sponsor Hubei Cancer Hospital
Collaborators: Yichang Central People's Hospital, Akeso Pharmaceuticals, Inc.
Conditions
(from sponsor)		 Locally Advanced Cervical Cancer, PD1, CTLA4
Related terms Uterine Cervical Neoplasms
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov